Circ Cardiovasc Interv:PCI治疗放射相关CAD的死亡率研究

2016-06-29 Mechront 译 MedSci原创

与标准的动脉粥样硬化性冠心病(CAD)患者相比,既往外照射治疗的CAD患者进行冠状动脉冠状动脉介入术(PCI)后,其短期和长期的死亡风险均增加。克利夫兰诊所心脏和血管研究所的Milind Y. Desai博士和同事对314名连续PCI治疗的患者进行了观察性研究。患者分两组:体外放射治疗的CAD组(EBRT;n = 157)和以前没有EBRT曝光的CAD患者(对照组;n = 157)。研究以全因死亡

与标准的动脉粥样硬化性冠心病(CAD)患者相比,既往外照射治疗的CAD患者进行冠状动脉冠状动脉介入术(PCI)后,其短期和长期的死亡风险均增加。

克利夫兰诊所心脏和血管研究所的Milind Y. Desai博士和同事对314名连续PCI治疗的患者进行了观察性研究。患者分两组:体外放射治疗的CAD组(EBRT;n = 157)和以前没有EBRT曝光的CAD患者(对照组;n = 157)。研究以全因死亡率为主要终点;心血管疾病死亡率为次要终点。

在平均随访6.6年后的年内,发生了101例死亡。EBRT组和对照组分别为59(59%)例和42 (42%)例(P = .04)。多变量Cox比例风险模型显示,以前的EBRT和全因死亡率存在持续性的关联,并且是独立的(HR = 1.85; 95% CI, 1.21-2.85)。

其他独立增加全因死亡率的因素包括球囊血管成形术或BMS置入位置 vs.DES置入位置(HR = 2.5; 95% CI, 1.61-3.97)、SYNTAX得分至少11(样本中位数;HR = 1.99;95% CI,1.32-3.04)、心功能III级或IV级(HR = 1.83;95% CI,1.15-2.91)、吸烟史(HR,1.88;95% CI,1.1-3.09)和年龄65岁以上(HR = 1.7;95% CI,1.07-2.07)。

69例患者发生了心血管疾病死亡,EBRT组和对照组分别为37 (54%)例和32 (46%)例。此外,EBRT组63%的死亡(n = 37)被确定为相关的心血管疾病原因。调整年龄、性别、NYHA心功能III级或IV级、SYNTAX得分和PCI类型后的非匹配分析显示,以前的EBRT暴露是心血管死亡率的持续性独立预测因子(aHR = 1.7; 95% CI, 1.06-2.89)。

研究结果表明,既往EBRT为PCI术后全因死亡率和心血管死亡的独立危险因素。

原始出处:

Reed GW, et al. Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention.Circ Cardiovasc Interv. 2016;doi:10.1161/CIRCINTERVENTIONS.115.003483.

Radiation-associated CAD confers increased mortality risk after PCI.Healio.June 28, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938603, encodeId=a4d2193860374, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 12 06:34:00 CST 2016, time=2016-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030088, encodeId=28922030088d6, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Feb 22 05:34:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148368, encodeId=7c951483681a, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:26:23 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132902, encodeId=ad931329028d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:16:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122109, encodeId=596912210937, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2016-09-12 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938603, encodeId=a4d2193860374, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 12 06:34:00 CST 2016, time=2016-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030088, encodeId=28922030088d6, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Feb 22 05:34:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148368, encodeId=7c951483681a, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:26:23 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132902, encodeId=ad931329028d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:16:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122109, encodeId=596912210937, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1938603, encodeId=a4d2193860374, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 12 06:34:00 CST 2016, time=2016-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030088, encodeId=28922030088d6, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Feb 22 05:34:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148368, encodeId=7c951483681a, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:26:23 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132902, encodeId=ad931329028d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:16:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122109, encodeId=596912210937, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2016-10-14 李东泽

    这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938603, encodeId=a4d2193860374, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 12 06:34:00 CST 2016, time=2016-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030088, encodeId=28922030088d6, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Feb 22 05:34:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148368, encodeId=7c951483681a, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:26:23 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132902, encodeId=ad931329028d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:16:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122109, encodeId=596912210937, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2016-09-22 李东泽

    很好,不错,以后会多学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1938603, encodeId=a4d2193860374, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Sep 12 06:34:00 CST 2016, time=2016-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030088, encodeId=28922030088d6, content=<a href='/topic/show?id=a96d13850d7' target=_blank style='color:#2F92EE;'>#PCI治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13850, encryptionId=a96d13850d7, topicName=PCI治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKUdkK5dVTue7YQDvwqM1ugOuEpDZEzvXhoGClFiavehcrNAYDuPbks3MkKLPpyAEicgic80KguxwicYQ/132, createdBy=ec952500165, createdName=ms5187542471278033, createdTime=Wed Feb 22 05:34:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148368, encodeId=7c951483681a, content=这篇咨询不错哦,值得学习,对于临床工作和科研思路都很有帮助。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Fri Oct 14 23:26:23 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=132902, encodeId=ad931329028d, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Thu Sep 22 10:16:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=122109, encodeId=596912210937, content=己拜读,受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sun Sep 11 08:59:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2016-09-11 1e10c84am36(暂无匿称)

    己拜读,受益匪浅

    0

相关资讯

WICCVD 2016:董念国——冠脉外科若干热点问题

2016年6月25日,由华中科技大学同济医学院附属协和医院主办的第三届武汉国际心血管病大会在武汉举行。冠心病外科治疗策略、技术、效果,一直是心血管外科关注热点,为此本届大会执行主席、华中科技大学同济医学院附属协和医院心脏大血管外科主任董念国教授在大会做了题为《冠脉外科若干热点问题》的学术报告,以下是详细内容:在介绍热点问题之前,董教授首先介绍了冠心病治疗发展的国内外趋势:国外趋势:以日本为例,

JAMA:胆固醇结晶栓塞知多少?蓝趾综合征-案例报道

患者男,70岁,就诊时有冠心病、高血压、轻度主动脉瓣狭窄出现精神状态改变、需要透析的急性肾损伤、四肢远端皮肤变色伴疼痛。3周前患者因心肌梗死行冠状动脉造影及冠状动脉旁路移植术。查体:如图所示,患者的几个脚趾跖侧有蓝色的斑块、丘疹,伴触痛;手上也有伴触痛的斑块。辅助检查:白细胞 9100/μL,嗜酸性粒细胞 22%;血尿素氮 70 mg/dL (25 mmol/L),肌酐 6.1 mg/dL (

解读|中国经皮冠状动脉介入治疗指南(2016)

2016年5月,《中国经皮冠状动脉介入治疗指南(2016)》正式更新。

2016ACC:值得关注的STEMI治疗领域重磅研究

2016年美国心脏病学会(ACC)科学年会已于4月2~4日在美国芝加哥成功召开。本文对在该大会上公布的STEMI治疗领域的最新研究进展进行了汇总。

中国PCI指南六大更新:稳定冠心病患者狭窄<90%,干预时需要有缺血证据

近日,《中国经皮冠状动脉介入治疗指南(2016)》发布。

PCI术中辅助支架精准定位的新方法—漂浮导丝和漂浮球囊技术

作者:李悦 公永太 孙党辉  哈尔滨医科大学附属第一医院PCI术中支架释放时保持支架位置稳定对于冠状动脉开口病变、分叉病变或其他需要支架精准定位释放的病变尤为重要。但有时由于心脏搏动可引起支架较大幅度位置移动,使支架精准定位释放困难,可能导致病变覆盖不完全、无病变节段或分支被支架覆盖等不良后果,严重者需置入另一枚支架补救,加重患者经济负担,且增加支架内血栓和再狭窄风险。 支架定位过程中